LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Shi, Yanbo; Harvey, Ian; Campopiano, Dominic; Sadler, Peter J. (2010)
Publisher: Hindawi Publishing Corporation
Journal: Bioinorganic Chemistry and Applications
Languages: English
Types: Article
Subjects: Chemistry, Inorganic chemistry, Q, QR, Research Article, QD146-197, QD1-999, Science, Article Subject
Ferric ion binding proteins (Fbps) transport FeIII across the periplasm and are vital for the virulence of many Gram negative\ud bacteria. Iron(III) is tightly bound in a hinged binding cleft with octahedral coordination geometry involving binding to protein\ud side chains (including tyrosinate residues) together with a synergistic anion such as phosphate. Niobium compounds are of\ud interest for their potential biological activity, which has been little explored. We have studied the binding of cyclopentadienyl\ud and nitrilotriacetato NbV complexes to the Fbp from Neisseria gonorrhoeae by UV-vis spectroscopy, chromatography, ICP-OES,\ud mass spectrometry, and Nb K-edge X-ray absorption spectroscopy. These data suggest that NbV binds strongly to Fbp and that a\ud dinuclear NbV centre can be readily accommodated in the interdomain binding cleft. The possibility of designing niobium-based\ud antibiotics which block iron uptake by pathogenic bacteria is discussed.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • [1] H. Ko¨pf and P. Ko¨pf-Maier, “Titanocene dichloride-the first metallocene with cancerostatic activity,” Angewandte Chemie International Edition, vol. 18, no. 6, pp. 477-478, 1979.
    • [2] P. Ko¨pf-Maier, “Development of necroses, virus activation and giant cell formation after treatment of Ehrlich ascites tumor with metallocene dichlorides,” Journal of Cancer Research and Clinical Oncology, vol. 103, no. 2, pp. 145-164, 1982.
    • [3] P. Ko¨pf-Maier, “Stage of pregnancy-dependent transplacental passage of 195mPt after cis-platinum treatment,” European Journal of Cancer and Clinical Oncology, vol. 19, no. 4, pp. 533- 536, 1983.
    • [4] P. Ko¨pf-Maier, “Tumor inhibition by titanocene complexes: influence upon two xenografted human lung carcinomas,” Journal of Cancer Research and Clinical Oncology, vol. 113, no. 4, pp. 342-348, 1987.
    • [5] P. Ko¨pf-Maier, “Tumor inhibition by titanocene complexes: influence on xenografted human adenocarcinomas of the gastrointestinal tract,” Cancer Chemotherapy and Pharmacology, vol. 23, no. 4, pp. 225-230, 1989.
    • [6] P. Ko¨pf-Maier, “Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma,” Anticancer Research, vol. 19, no. 1A, pp. 493-504, 1999.
    • [7] P. Ko¨pf-Maier and H. Ko¨pf, “Antitumor metallocenes: new developments and toxicologic features,” Anticancer Research, vol. 6, no. 2, pp. 227-233, 1986.
    • [8] P. Ko¨pf-Maier and H. Ko¨pf, “Tumor inhibition by titanocene complexes. Activity against B16 melanoma and colon 38 carcinoma,” Arzneimittel-Forschung, vol. 37, no. 5, pp. 532- 534, 1987.
    • [9] P. Ko¨pf-Maier, M. Leitner, R. Voigtla¨nder, and H. Ko¨pf, “Molybdocen-dichlorid als antitumor-agens,” Zeitschrift fu¨r Naturforschung C, vol. 34, no. 12, pp. 1174-1176, 1979.
    • [10] N. Kro¨ger, U. R. Kleeberg, K. Mross, L. Edler, G. Saß, and D. K. Hossfeld, “Phase II clinical trial of titanocene dichloride in patients with metastatic breast cancer,” Onkologie, vol. 23, no. 1, pp. 60-62, 2000.
    • [11] M. M. Harding and G. Mokdsi, “Antitumour metallocenes: structure-activity studies and interactions with biomolecules,” Current Medicinal Chemistry, vol. 7, no. 12, pp. 1289-1303, 2000.
    • [12] P. Ko¨pf-Maier and T. Kapo¨tke, “Antitumor activity of ionic niobocene and molybdenocene complexes in high oxidation states,” Journal of Cancer Research and Clinical Oncology, vol. 118, no. 3, pp. 216-221, 1992.
    • [13] P. Ko¨pf-Maier and H. Ko¨pf, “Non-platinum-group metal antitumor agents: history, current status, and perspectives,” Chemical Reviews, vol. 87, no. 5, pp. 1137-1152, 1987.
    • [14] P. Ko¨pf-Maier, M. Leitner, and H. Ko¨pf, “Tumor inhibition by metallocenes: antitumor activity of niobocene and tungstocene dichlorides,” Journal of Inorganic and Nuclear Chemistry, vol. 42, no. 12, pp. 1789-1791, 1980.
    • [15] M. M. Harding, M. Prodigalidad, and M. J. Lynch, “Organometallic anticancer agents. 2. Aqueous chemistry and interaction of niobocene dichloride with nucleic acid constituents and amino acids,” Journal of Medicinal Chemistry, vol. 39, no. 25, pp. 5012-5016, 1996.
    • [16] C. Ratledge, “Iron metabolism and infection,” Food and Nutrition Bulletin, vol. 28, no. 4, supplement, pp. S515-S523, 2007.
    • [17] U. E. Schaible and S. H. E. Kaufmann, “Iron and microbial infection,” Nature Reviews Microbiology, vol. 2, no. 12, pp. 946-953, 2004.
    • [18] I. J. Schalk, “Metal trafficking via siderophores in Gramnegative bacteria: specificities and characteristics of the pyoverdine pathway,” Journal of Inorganic Biochemistry, vol. 102, no. 5-6, pp. 1159-1169, 2008.
    • [19] A. J. Nowalk, S. B. Tencza, and T. A. Mietzner, “Coordination of iron by the ferric iron-binding protein of pathogenic Neisseria is homologous to the transferrins,” Biochemistry, vol. 33, no. 43, pp. 12769-12775, 1994.
    • [20] W. Zhong, D. Alexeev, I. Harvey, et al., “Assembly of an oxozirconium(IV) cluster in a protein cleft,” Angewandte Chemie International Edition, vol. 43, no. 44, pp. 5914-5918, 2004.
    • [21] W. Zhong, J. A. Parkinson, M. Guo, and P. J. Sadler, “Unusual features for zirconium(IV) binding to human serum transferrin,” Journal of Biological Inorganic Chemistry, vol. 7, no. 6, pp. 589-599, 2002.
    • [22] H. Zhu, D. Alexeev, D. J. B. Hunter, D. J. Campopiano, and P. J. Sadler, “Oxo-iron clusters in a bacterial iron-trafficking protein: new roles for a conserved motif,” Biochemical Journal, vol. 376, no. 1, pp. 35-41, 2003.
    • [23] M. Guo, I. Harvey, D. J. Campopiano, and P. J. Sadler, “Short oxo-titanium(IV) bond in bacterial transferrin: a protein target for metalloantibiotics,” Angewandte Chemie International Edition, vol. 45, no. 17, pp. 2758-2761, 2006.
    • [24] C. Ferreiro´ s, M. T. Criado, and J. A. Go´ mez, “The neisserial 37 kDa ferric binding protein (FbpA),” Comparative Biochemistry and Physiology B, vol. 123, no. 1, pp. 1-7, 1999.
    • [25] P. Ellis, Studies of metalloproteins using EXAFS and XPD, Ph.D. thesis, University of Sydney, Sydney, Australia, 1995.
    • [26] J. J. Rehr and R. C. Albers, “Scattering-matrix formulation of curved-wave multiple-scattering theory: application to X-rayabsorption fine structure,” Physical Review B, vol. 41, no. 12, pp. 8139-8149, 1990.
    • [27] N. Binsted, EXCURV98: CCLRC Daresbury Laboratory Computer Program, CCLRC Daresbury Laboratory, Warrington, UK, 1998.
    • [28] L. Hedin, A. Johansso, Bi. Lundqvis, S. Lundqvis, and V. Samathiy, “Effects of electron-electron interaction on oneelectron properties of atoms and solids,” Arkiv fo¨r Fysik, vol. 39, no. 2, p. 97, 1969.
    • [29] J. J. Rehr, J. M. de Leon, S. I. Zabinsky, and R. C. Albers, “Theoretical X-ray absorption fine structure standards,” Journal of the American Chemical Society, vol. 113, no. 14, pp. 5135-5140, 1991.
    • [30] M. Guo, I. Harvey, W. Yang, et al., “Synergistic anion and metal binding to the ferric ion-binding protein from Neisseria gonorrhoeae,” Journal of Biological Chemistry, vol. 278, no. 4, pp. 2490-2502, 2003.
    • [31] G. M. Then, H. Appel, J. Duffield, D. M. Taylor, and W.-G. Thies, “In vivo and in vitro studies of hafnium-binding to rat serum transferrin,” Journal of Inorganic Biochemistry, vol. 27, no. 4, pp. 255-270, 1986.
    • [32] M. Guo, H. Sun, H. J. McArdle, L. Gambling, and P. J. Sadler, “Ti(IV) uptake and release by human serum transferrin and recognition of Ti(IV)-transferrin by cancer cells: understanding the mechanism of action of the anticancer drug titanocene dichloride,” Biochemistry, vol. 39, no. 33, pp. 10023-10033, 2000.
    • [33] H. Sun, H. Li, and P. J. Sadler, “Transferrin as a metal ion mediator,” Chemical Reviews, vol. 99, no. 9, pp. 2817-2842, 1999.
    • [34] C. M. Bruns, D. S. Anderson, K. G. Vaughan, et al., “Crystallographic and biochemical analyses of the metal-free Haemophilus influenzae Fe3+-binding protein,” Biochemistry, vol. 40, no. 51, pp. 15631-15637, 2001.
    • [35] D. Alexeev, H. Zhu, M. Guo, et al., “A novel protein-mineral interface,” Nature Structural Biology, vol. 10, no. 4, pp. 297- 302, 2003.
    • [36] D. Homden, C. Redshaw, J. A. Wright, D. L. Hughes, and M. R. J. Elsegood, “Early transition metal complexes bearing a C-capped tris(phenolate) ligand incorporating a pendant imine arm: synthesis, structure, and ethylene polymerization behavior,” Inorganic Chemistry, vol. 47, no. 13, pp. 5799-5814, 2008.
    • [37] A. V. Gerasimenko, M. A. Pushilin, and R. L. Davidovich, “Disordering of the [NbOF5]2− complex anions in bis(glycinium) pentafluoridooxidoniobate(V) and bis(β- alaninium) pentafluoridooxidoniobate(V) dihydrate,” Acta Crystallographica C, vol. 64, part 11, pp. m358-m361, 2008.
    • [38] S. K. Park, S. M. Koo, and Y. E. Lee, “Heterometallic lithium niobium complexes: synthesis and molecular structures of LiNbO(O-2, 6-PhMe2)4·3THF and [LiNbCl3(O-2, 6-PhMe2)2 · 2THF]2,” Polyhedron, vol. 19, no. 9, pp. 1037- 1041, 2000.
    • [39] M. K. Van Bael, I. Arcon, K. Van Werde, D. Nelis, J. Mullens, and L. C. Van Poucke, “Structure determination by EXAFS of Nb-peroxo-citrato complexes in aqueous solutiongel systems,” Physica Scripta, vol. T115, pp. 415-417, 2005.
    • [40] M. Pintor, L. Ferro´ n, J. A. Go´ mez, A. Gorringe, M. T. Criado, and C. M. Ferreiro´ s, “Blocking of iron uptake by monoclonal antibodies specific for the Neisseria meningitidis transferrinbinding protein 2,” Journal of Medical Microbiology, vol. 45, no. 4, pp. 252-257, 1996.
    • [41] C. Ferreiro´ s, M. T. Criado, and J. A. Go´ mez, “The neisserial 37 kDa ferric binding protein (FbpA),” Comparative Biochemistry and Physiology B, vol. 123, no. 1, pp. 1-7, 1999.
    • [42] H. Boukhalfa, D. S. Anderson, T. A. Mietzner, and A. L. Crumbliss, “Kinetics and mechanism of iron release from the bacterial ferric binding protein nFbp: exogenous anion influence and comparison with mammalian transferrin,” Journal of Biological Inorganic Chemistry, vol. 8, no. 8, pp. 881- 892, 2003.
    • [43] J. A. Go´ mez, M. T. Criado, and C. M. Ferreiro´ s, “Bactericidal activity of antibodies elicited against the Neisseria meningitidis 37-kDa ferric binding protein (FbpA) with different adjuvants,” FEMS Immunology and Medical Microbiology, vol. 20, no. 1, pp. 79-86, 1998.
    • [44] E. Banin, A. Lozinski, K. M. Brady, et al., “The potential of desferrioxamine-gallium as an anti-Pseudomonas therapeutic agent,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 43, pp. 16761-16766, 2008.
  • No related research data.
  • No similar publications.
  • BioEntity Site Name
    2thfProtein Data Bank
    3thfProtein Data Bank